An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Ropinirole (Primary) ; Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics; Proof of concept
- Sponsors Titan Pharmaceuticals
- 11 Aug 2017 Status changed from planning to not yet recruiting.
- 17 May 2017 Planned initiation date changed from 1 Jun 2016 to 1 Sep 2017.
- 10 May 2017 According to a Titan Pharmaceuticals media release, the company expects to initiate this study in the third quarter of 2017.